# Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

> **NCT05110742** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 64 (estimated)

## Conditions studied

- Hematological Malignancy

## Interventions

- **DRUG:** Fludarabine Phosphate
- **DRUG:** Cyclophosphamide
- **DRUG:** CAR.5/IL15-transduced CB-NK cells

## Key facts

- **NCT ID:** NCT05110742
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05110742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05110742, "Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05110742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*